A new review in Ferroptosis and Oxidative Stress examines whether one class of compounds could suppress two interconnected forms of regulated cell death at the same time. The article, titled “NecroFerrins as dual therapeutic inhibitors targeting necroptosis and ferroptosis,” explores the emerging idea that necroptosis and ferroptosis may be treated more effectively through coordinated pharmacological intervention rather than by blocking either pathway separately. The authors, Claire Delehouzé and Stéphane Bach, describe these proposed dual-action molecules as “NecroFerrins” and discuss their potential relevance to diseases in which inflammatory signaling, oxidative stress, and tissue injury occur simultaneously.
Necroptosis and ferroptosis are distinct biological programs, but both can culminate in catastrophic loss of plasma-membrane integrity and the release of inflammatory intracellular contents. Necroptosis is a kinase-driven form of regulated necrosis that is typically associated with the receptor-interacting protein kinase 1, receptor-interacting protein kinase 3, and mixed lineage kinase domain-like pseudokinase axis. In response to signals such as tumor necrosis factor, pathogen-associated stress, damage-associated molecular patterns, or certain chemical insults, RIPK1 and RIPK3 can assemble into a signaling platform known as the necrosome. This promotes phosphorylation and oligomerization of MLKL, which then moves to the plasma membrane and disrupts its architecture. The resulting cellular rupture can release damage-associated molecular patterns and amplify local inflammation.
Ferroptosis follows a different molecular route. It is driven by iron-dependent oxidative damage to membrane lipids, particularly phospholipids containing polyunsaturated fatty acids. When intracellular iron availability and reactive oxygen species increase, susceptible lipids can undergo a chain reaction of peroxidation. Under normal conditions, antioxidant systems limit this process. Glutathione peroxidase 4 is one of the principal defenses because it reduces toxic lipid hydroperoxides to less-reactive lipid alcohols. Ferroptosis suppressor protein 1 provides another protective mechanism by supporting the regeneration of reduced coenzyme Q10, a radical-trapping antioxidant. When these systems are overwhelmed or disabled, lipid peroxide accumulation destabilizes membranes and can ultimately produce irreversible cell damage.
Although the initiating signals differ, the two pathways can be influenced by overlapping cellular conditions. Redox imbalance, mitochondrial dysfunction, altered lipid metabolism, iron handling, and inflammatory signaling may affect both necroptotic and ferroptotic sensitivity. In some disease settings, suppression of one form of regulated death may also shift cellular stress toward another. This possibility is particularly important in acute and chronic organ injuries, where damaged tissues may contain multiple cell populations exposed to cytokines, hypoxia, metabolic disruption, and oxidative stress at the same time. According to the review, these interconnections create a rationale for investigating compounds that can modulate more than one regulated-death mechanism.
The NecroFerrin concept is based on combining two pharmacological activities within a single molecular framework. One activity would interfere with necroptotic signaling, potentially by inhibiting RIPK1-dependent events. The second would limit the propagation of lipid radicals and thereby reduce ferroptotic membrane damage. The review highlights RIPROStatins as an example of this strategy. These compounds are described as combining RIPK1 inhibition with radical-trapping antioxidant properties, bringing together suppression of a protein-kinase-controlled pathway and chemical interception of the lipid oxidation reactions that drive ferroptosis. Such a design is intended to address both upstream signaling and downstream membrane injury.
The proposed mechanism also involves molecular systems that connect protein quality control with oxidative cell death. The review discusses heat shock protein 90 as one example of a cellular chaperone that can influence these pathways. HSP90 helps stabilize and regulate numerous proteins, and it may participate in chaperone-mediated autophagic degradation of GPX4 under certain conditions. Because GPX4 is central to the removal of lipid peroxides, changes in its abundance or activity can strongly affect ferroptotic vulnerability. This relationship illustrates why a compound’s effects may extend beyond a single signaling protein: cellular chaperones, autophagy, antioxidant capacity, iron metabolism, and membrane composition can collectively determine whether a stressed cell survives or crosses the threshold into regulated necrosis.
The review places NecroFerrins within the broader field of polypharmacology, which seeks to use one compound to influence several biologically connected targets. In complex diseases, single-target drugs may be limited by pathway redundancy, compensatory signaling, or the simultaneous activation of multiple injury programs. A molecule that blocks RIPK1-dependent necroptosis while also neutralizing lipid radicals could, in principle, provide broader protection than either a selective necroptosis inhibitor or a ferroptosis inhibitor alone. However, the authors emphasize that dual activity does not automatically translate into therapeutic success. The balance between potency, selectivity, tissue distribution, metabolic stability, and toxicity will determine whether such molecules can be developed into useful treatments.
This caution is especially relevant because necroptosis and ferroptosis are not exclusively harmful processes in every biological context. Regulated cell death contributes to host defense, tissue remodeling, elimination of damaged cells, and responses to infection. Broadly suppressing these mechanisms could therefore interfere with beneficial immune or homeostatic functions. In addition, the same compound may behave differently across organs because cells vary in their expression of RIPK1, RIPK3, MLKL, GPX4, FSP1, antioxidant enzymes, iron-storage proteins, and lipid-processing pathways. Rigorous studies will be required to establish whether a candidate NecroFerrin acts through the intended mechanisms in living tissues and whether it can protect organs without producing undesirable immunological or metabolic effects.
The authors present the dual-inhibition concept as a framework for future chemical biology rather than as a completed therapeutic solution. Experimental validation will need to distinguish direct pathway inhibition from nonspecific antioxidant or cytoprotective effects. Researchers will also need to determine how these molecules perform in disease models involving ischemia-reperfusion injury, inflammation, infection, neurodegeneration, or organ fibrosis, where regulated cell-death pathways may operate simultaneously. Biomarkers of necroptosis, ferroptosis, lipid peroxidation, iron status, and inflammatory damage could help identify patients or disease stages most likely to benefit. By viewing regulated cell death as an interconnected network, the review argues that future drug discovery may move beyond the question of how to inhibit one pathway and instead ask whether several converging mechanisms can be controlled with a carefully designed single molecule.
Subject of Research: Cells
Article Title: NecroFerrins as dual therapeutic inhibitors targeting necroptosis and ferroptosis
Web References: https://doi.org/10.70401/fos.2026.0041 ; https://smart.servier.com/ ; https://creativecommons.org/licenses/by/4.0/
References: Delehouzé, Claire, and Stéphane Bach. “NecroFerrins as dual therapeutic inhibitors targeting necroptosis and ferroptosis.” Ferroptosis and Oxidative Stress. DOI: 10.70401/fos.2026.0041.
Image Credits: Claire Delehouzé and Stéphane Bach, 2027; adapted from Servier Medical Art, licensed under CC BY 4.0.
Keywords: Necroptosis, ferroptosis, NecroFerrins, RIPK1, RIPK3, MLKL, lipid peroxidation, GPX4, FSP1, oxidative stress, regulated cell death, polypharmacology, RIPROStatins
